Nadir Ali, MD
Cardiology · Webster, TXNPI 1356383103
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Boston Scientific at 26.3% of the total. 2025 is the largest year on record at $1,091, 8.5 times the $129 reported in 2019.
Across 97 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$851
- Abbott$537
- Johnson & Johnson$318
- Abiomed$257
- Impulse Dynamics (USA) Inc.$134
- Edwards Lifesciences$130
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,225100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $851 |
| Abbott | 15 | $537 |
| Johnson & Johnson | 15 | $318 |
| Abiomed | 5 | $257 |
| Impulse Dynamics (USA) Inc. | 2 | $134 |
| Edwards Lifesciences | 2 | $130 |
| AstraZeneca | 2 | $128 |
| E.r. Squibb & Sons, L.L.C. | 7 | $111 |
| Scpharmaceuticals Inc. | 4 | $88 |
| Novo Nordisk | 4 | $87 |
| Novartis | 4 | $81 |
| Pfizer | 4 | $78 |
| Medtronic | 1 | $71 |
| Merck | 4 | $59 |
| Baxter Healthcare | 2 | $47 |
| Boehringer Ingelheim | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $32 |
| Teleflex LLC | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Avinger Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Elutia, Inc. | 1 | $13 |
| Preventice Services, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myLUX Patient Kit with mobile device$173
- CARDIOMEMS$150
- EKOSONIC$148
- SAPIEN 3 Ultra RESILIA$114
- FARXIGA$110
- ACUITY Steerable$109
- Impella$100
How this compares
$3,231 in reported general payments places this provider in the 75th percentile of 33 cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $306,318 |
| XareltoRivaroxaban | 105 | $145,403 |
| OzempicSemaglutide | 57 | $58,132 |
| EntrestoSacubitril/Valsartan | 56 | $57,719 |
| BrilintaTicagrelor | 48 | $38,567 |
| ClopidogrelClopidogrel Bisulfate | 637 | $7,421 |
| Metoprolol Succinate | 478 | $7,126 |
| Prasugrel Hcl | 52 | $6,071 |
| Losartan Potassium | 327 | $3,429 |
| Digoxin | 103 | $2,875 |
| Amlodipine Besylate | 433 | $2,555 |
| SotalolSotalol Hcl | 109 | $2,379 |
| Metoprolol Tartrate | 325 | $2,076 |
| Potassium Chloride | 99 | $1,946 |
| Spironolactone | 206 | $1,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $306,318237 claims |
| Johnson & JohnsonXarelto | $318 | $145,403105 claims |
| Novo NordiskOzempic | $87 | $58,13257 claims |
| NovartisEntresto | $81 | $57,71956 claims |
| AstraZenecaBrilinta | $128 | $38,56748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 cardiology providers in Texas.
Other cardiology in Webster
- Harvey SluskyWebster$26K
- Shiny MathewkuttyDallas$24K
- Sheikh AhmedHouston$14K
- Lane MillerCollege Station$11K
- Ramon TyHouston$11K
- Faizan IftikharMcKinney$7K
- Thieu NguyenHouston$5K
- Nadim ZaccaHouston$2K
- Adeniran AriyoDallas$1K
- Ralph NimchanLaredo$702
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.